Charles Schwab
MRSN

Charles Schwab’s Mersana Therapeutics MRSN Stock Holding History

Charles Schwab’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,225
Closed -$96.6K – 3541
2025
Q1 		$96.6K Sell
11,225
-1,280
-10% -$19.8K ﹤0.01% 3345
2024
Q4 		$447K Hold
12,505
– – ﹤0.01% 3172
2024
Q3 		$591K Hold
12,505
– – ﹤0.01% 3105
2024
Q2 		$628K Buy
12,505
+670
+6% +$48.4K ﹤0.01% 3098
2024
Q1 		$1.33M Sell
11,835
-488
-4% -$48.5K ﹤0.01% 2710
2023
Q4 		$715K Buy
12,323
+547
+5% +$22K ﹤0.01% 2948
2023
Q3 		$374K Sell
11,776
-21,052
-64% -$1M ﹤0.01% 3154
2023
Q2 		$2.7M Buy
32,828
+3,641
+12% +$533K ﹤0.01% 2459
2023
Q1 		$3M Buy
29,187
+2,346
+9% +$329K ﹤0.01% 2413
2022
Q4 		$3.93M Buy
26,841
+1,095
+4% +$185K ﹤0.01% 2338
2022
Q3 		$4.35M Sell
25,746
-501
-2% -$81.4K ﹤0.01% 2288
2022
Q2 		$3.03M Buy
26,247
+7,661
+41% +$721K ﹤0.01% 2411
2022
Q1 		$1.85M Sell
18,586
-934
-5% -$109K ﹤0.01% 2672
2021
Q4 		$3.04M Buy
19,520
+228
+1% +$44.4K ﹤0.01% 2566
2021
Q3 		$4.55M Buy
19,292
+2,793
+17% +$816K ﹤0.01% 2423
2021
Q2 		$5.6M Buy
16,499
+1,692
+11% +$641K ﹤0.01% 2297
2021
Q1 		$5.99M Buy
14,807
+477
+3% +$231K ﹤0.01% 2206
2020
Q4 		$9.53M Buy
14,330
+191
+1% +$106K ﹤0.01% 1895
2020
Q3 		$6.58M Buy
14,139
+9,391
+198% +$4.75M ﹤0.01% 1938
2020
Q2 		$2.78M Buy
4,748
+1,304
+38% +$445K ﹤0.01% 2300
2020
Q1 		$502K Buy
3,444
+42
+1% +$7.34K ﹤0.01% 2713
2019
Q4 		$488K Hold
3,402
– – ﹤0.01% 2823
2019
Q3 		$135K Hold
3,402
– – ﹤0.01% 3081
2019
Q2 		$345K Buy
3,402
+2,008
+144% +$237K ﹤0.01% 2971
2019
Q1 		$184K Buy
1,394
+414
+42% +$52.1K ﹤0.01% 3037
2018
Q4 		$100K Sell
980
-144
-13% -$22.8K ﹤0.01% 3089
2018
Q3 		$281K Buy
1,124
+144
+15% +$48.3K ﹤0.01% 3019
2018
Q2 		$438K Buy
980
+168
+21% +$73.7K ﹤0.01% 2846
2018
Q1 		$321K Buy
+812
New +$321K ﹤0.01% 2854

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Charles Schwab's MRSN Position: Q2 2025 in Review

Charles Schwab sold out of Mersana Therapeutics (MRSN) in Q2 2025, closing a stake of 11,225 shares — an estimated $96.6K sold.

Charles Schwab first reported a position in MRSN in Q1 2018 and held it in 29 quarters. The position peaked at $9.53M in Q4 2020. 83 funds tracked by Wall St. Rank hold MRSN as of Q2 2025.

  • Charles Schwab reported no remaining Mersana Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Charles Schwab sold 11,225 Mersana Therapeutics shares in Q2 2025, an estimated $96.6K.
  • Charles Schwab first reported a position in Mersana Therapeutics in Q1 2018 and held it in 29 quarters.
  • Charles Schwab's Mersana Therapeutics position peaked at $9.53M in Q4 2020.
  • 83 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2025.

Based on Charles Schwab's 13F filing for Q2 2025, filed 12 Aug 2025.